TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.

Gilberto de Castro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.